Navigation Links
Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4

INDIANAPOLIS, Sept. 1, 2011 /PRNewswire/ -- Roche Diabetes Care, makers of the ACCU-CHEK® portfolio of diabetes management products and services, is proud to host its second annual Infusion Site Awareness Week, Aug. 29-Sept. 4, a week-long effort to highlight the importance of proper infusion site management for the 400,000 people in the United States with Type 1 diabetes who use an insulin pump.

"The inaugural Infusion Site Awareness Week, which was launched during the 2010 annual American Association of Diabetes Educators (AADE) conference, helped us reach hundreds of diabetes educators and people living with Type 1 diabetes who are now better able to identify and address potential complications stemming from improper site management," said Roche Diabetes Care North America Medical Director Andreas Stuhr, M.D.

According to the Juvenile Diabetes Research Foundation (JDRF), a supporting partner for this year's campaign, as many as 3 million Americans live with type 1 diabetes, and about 15,000 children and 15,000 adults are diagnosed with the disease every year.  

"Living with type 1 diabetes requires a person to be extremely aware and knowledgeable about the disease," said Aaron Kowalski, Ph.D., Assistant Vice President of Treatment Therapies for JDRF. "In addition to monitoring blood sugar and adjusting diet and exercise, proper infusion site rotation and care is an often underemphasized, but very important part of good diabetes management. Infusion Site Awareness Week is a perfect opportunity for diabetes educators to discuss the importance of best practices for insulin pump usage with their patients, both new and old."

For people with diabetes using insulin pump therapy, the infusion site is where an insulin pump's plastic cannula or steel needle is placed under the user's skin to administer insulin. Infusion site management is the practice of choosing a site, cleaning and preparing it, properly inserting a cannula or needle, monitoring insulin flow and then regularly rotating the insertion site to avoid infection and ensure appropriate insulin delivery. In most cases, this site must be changed every one to three days and the same site must not be reused for about two weeks or until the site has fully healed.

Roche started the annual initiative last year to increase understanding and education about proper infusion site management. A 2007 study in the American Diabetes Association journal Diabetes Care reported that some adult patients experience as many as 12 issues of irritation or infection a year because of improper site maintenance. The authors concluded that "efforts to minimize the risk of irritation, scarring, and infection should include strict adherence to proper infusion site preparation, catheter insertion, and site rotation."(1)

To help increase education, Roche is distributing Infusion Site Awareness Week kits to certified diabetes educators throughout the U.S. These kits include an educational DVD explaining proper site maintenance, fact sheets to help facilitate discussions and promotional materials such as bracelets, temporary tattoos, logos and press materials to help with outreach within their communities. Information can also be found at

In addition to the kits, Roche is taking the conversation on infusion site management to the social web. Follow the Infusion Site Awareness movement on Twitter @infusionsite for regular updates about healthy living, diabetes management, and other important news.

"The prospect of constant finger pricks, strict diets and wearing an insulin pump all day can be devastating to newly diagnosed diabetes patients," Dr. Stuhr said. "With Infusion Site Awareness Week, we hope to make living with diabetes a little easier, a little less scary, and help people develop life-long practices that will lead to more healthy lives."

For more information, go to

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management—from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information, please visit

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:
Todd A. Siesky
Public Relations Manager
Roche Diabetes Care
9115 Hague Road, Building H
Indianapolis, IN 46250-0457
Phone: +1-317-521-3966

(1) Phillip, Moshe, MD, Battelino, Tadej , MD, PhD, Rodriguez, Henry, Danne, Thomas, MD, and Kaufman, Francine. "Use of Insulin Pump Therapy in the Pediatric Age-Group." DiabetesCare 30.6 (2007): 1653-1662.

SOURCE Roche Diabetes Care
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):